A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Aún no traducido Aún no traducido
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2011
Cargando información sobre las referencias
This study (UNITI-1) will compare the effects (both positive and negative) of an initial treatment with ustekinumab to placebo over 8 weeks, in patients with moderately to severely active Crohn\'s disease who have either failed or could not tolerate at least one TNF-antagonist medications in the past (specifically, infliximab, adalimumab, or certolizumab pegol).
Epistemonikos ID: 4cabb4b5d90cf69ac7258db439fb5ee29a38c40d
First added on: Jul 30, 2018